Discover investment opportunities in Gene Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Gene Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Gene Stocks using our Smart AI Filter.
9 stocks found for "Gene Stocks"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
2.51 | ±100.0% | -1.1 | 0.00% | |||
0.36 | ±26.9% | 24.5 | 0.00% | |||
2.32 | ±96.8% | -0.7 | 0.00% | |||
1.92 | ±68.6% | -1.9 | 0.00% | |||
1.34 | ±55.5% | -10.4 | 0.00% | |||
2.18 | ±100.0% | -0.9 | 0.00% | |||
0.89 | ±41.9% | 22.8 | 0.00% | |||
2.26 | ±100.0% | -7.6 | 0.00% | |||
0.92 | ±45.4% | -143.2 | 0.00% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: What attracts investors to CRISPR Therapeutics (CRSP)?
A: CRISPR Therapeutics is recognized for its innovative gene-editing technology, which holds potential in treating genetic disorders. Its collaborations and pipeline progress can be attractive for those interested in cutting-edge biotechnology.
Q: Does Editas Medicine (EDIT) offer significant growth potential for investors?
A: Editas Medicine focuses on transformative CRISPR-based therapies. While its growth potential is high due to the innovative nature of its research, investors should consider the inherent risks associated with biotech development stages.
Q: How does Beam Therapeutics (BEAM) stand out in the gene-editing sector?
A: Beam Therapeutics utilizes base editing technology, offering a unique approach compared to traditional CRISPR. This differentiation might intrigue investors looking for innovative solutions within the biotech space.
Q: What risk factors are associated with investing in Intellia Therapeutics (NTLA)?
A: Intellia Therapeutics, like many biotech companies, faces risks such as clinical trial outcomes, regulatory hurdles, and competition within the gene-editing market. Investors should assess these alongside its promising technology.
Q: Does Sangamo Therapeutics (SGMO) provide opportunities for income-driven investors?
A: Sangamo Therapeutics primarily focuses on research and development, meaning it may not currently prioritize dividends. Income-focused investors might explore alternative biotech stocks that offer dividends.
Q: What sector-specific opportunities does Fate Therapeutics (FATE) present?
A: Fate Therapeutics works on cellular immunotherapies, targeting cancer and immune disorders. This emerging field potentially offers significant opportunities if their treatments demonstrate efficacy and scalability.